A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Iconic Therapeutics, Inc.8 sites in 1 country15 target enrollmentMarch 26, 2018

ConditionsChoroidal Neovascularization Wet Macular Degeneration

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Choroidal Neovascularization
Sponsor: Iconic Therapeutics, Inc.
Enrollment: 15
Locations: 8
Primary Endpoint: Change in Choroidal Neovascularization (CNV) Over Time
Status: Terminated
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

Registry

clinicaltrials.gov

Start Date

March 26, 2018

End Date

April 25, 2019

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Iconic Therapeutics, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Males or females of any race, ≥50 years of age
•Active primary CNV secondary to AMD in the study eye

Exclusion Criteria

•Any prior treatment of CNV or advanced AMD in the study eye, except for dietary supplements or vitamins
•Any intraocular or ocular surface surgery (including cataract surgery and laser procedures) in the study eye within 3 months
•Vitrectomy in the study eye